Immupharma PLC Admission of new ordinary shares of GBP0.01 (5391Q)
June 28 2022 - 12:44PM
UK Regulatory
TIDMIMM
RNS Number : 5391Q
Immupharma PLC
28 June 2022
28 June 2022
ImmuPharma PLC
("ImmuPharma" or the "Company")
Admission of new ordinary shares of GBP0.01 following share
capital reorganisation
At the AGM held earlier today, shareholders approved a
resolution to sub-divide each existing ordinary share of GBP0.10
nominal value in the capital of the Company ("Existing Ordinary
Shares")into one ordinary share of GBP0.01 each nominal value; and
one deferred share of GBP0.09 each (these deferred shares have no
voting rights, and no practical value).
Application has today been made for 284,984,933 ordinary shares
of GBP0.01 ("New Ordinary Shares") to be admitted to trading on
AIM. Admission is expected on or around Monday 4 July 2022.
The ISIN code of the New Ordinary Shares of GBP0.01 nominal
value will remain the same (GB0033711010) as for the previous
ordinary shares of GBP0.10 nominal value.
Following Admission each shareholders will hold the same number
of New Ordinary Shares as they held of Existing Ordinary
Shares.
Total Voting Rights
Following Admission, the Company's issued share capital will
comprise 284,984,933 Ordinary Shares of GBP0.01 each with one
voting right each. As the Company does not hold any shares in
Treasury, the total number of voting rights in the Company is also
284,984,933 and this figure of Ordinary Shares may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman and Chief Executive
Officer +44 (0) 207 206 2650
Lisa Baderoon, Head of Investor Relations
& Non-Executive Director + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes, Bob Pountney +44 (0) 20 3650 3650
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases and anti-infectives. The lead program,
Lupuzor(TM), within our P140 platform, is a first-in class
autophagy immunomodulator which is in Phase 3 for the treatment of
Lupus, a debilitating and potentially life threatening auto immune
disease. Preclinical analysis suggests therapeutic activity for
many other autoimmune diseases targeted through our P140 platform,
that share the same autophagy mechanism of action.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDZGZVVRFGZZM
(END) Dow Jones Newswires
June 28, 2022 12:44 ET (16:44 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024